Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the Functional Materials business, customer inquiries and sales of materials for the pharmaceutical and medical fields and semiconductor-related materials were strong. In the Bio business, sales of products at the mass-production and development stages were strong. The profit contribution from higher revenue more than offset increases in depreciation, labor costs and other expenses associated with the operation of FP-4.
No matters to report
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥4,466 million (YoY +32.4%) |
| Operating profit | ¥311 million |
| Ordinary income | ¥304 million |
| Profit attributable to owners of the parent | ¥197 million |
| Net income per share | ¥25.64 |
| Equity ratio | End of the current fiscal period 67.1 / End of previous period 65.1 |
| Total assets | ¥20,894 million |
| Net assets | ¥14,023 million |
| Cash flows from operating activities | ¥1,150,564 thousand |
| Cash flows from investing activities | ¥-216,787 thousand |
| Cash flows from financing activities | ¥-838,849 thousand |
| Cash and cash equivalents at end of period | ¥2,268,188 thousand |
| Full-year earnings forecast | Net Sales ¥10,000 million (YoY +10.0%) / Operating profit ¥910 million (YoY -11.2%) / Ordinary income ¥890 million (YoY -13.5%) / Net income ¥640 million (YoY -16.5%) |
| Annual Dividend Forecast | ¥33 → ¥33（0.0%） |
| Segment revenue | Functional Materials business segment ¥1,768,408 thousand (YoY +25.4%), Pharmaceuticals business segment ¥1,341,712 thousand (YoY -5.3%), Biotechnology division ¥1,356,175 thousand (YoY +147.6%) |
| Depreciation and amortization | ¥813,572 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets ¥94 thousand, Insurance proceeds received ¥15,914 thousand / Extraordinary loss Loss on disposal of fixed assets ¥0 thousand, Loss on valuation of investment securities ¥21,304 thousand |
| Disclosure regarding the going concern assumption | No matters to report |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 7,779,900 Shares |
| Treasury Shares at Period-End | 150,380 Shares |
| Factors Behind Changes in Business Performance | In the Functional Materials business, customer inquiries and sales of materials for the pharmaceutical and medical fields and semiconductor-related materials were strong. In the Bio business, sales of products at the mass-production and development stages were strong. The profit contribution from higher revenue more than offset increases in depreciation, labor costs and other expenses associated with the operation of FP-4. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Functional Materials business, customer inquiries and sales of materials for the pharmaceutical and medical fields and semiconductor-related materials were strong. In the Bio business, sales of products at the mass-production and development stages were strong, and the profit contribution from higher revenue more than offset increases in depreciation, labor costs and other expenses associated with the operation of FP-4.